Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.

View Candidate
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Announces First Quarter 2018 Financial Update

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including…

Read this Press Release: Poxel Announces First Quarter 2018 Financial Update

Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases,…

Read this Press Release: Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference

Poxel Provides Business Update and Reports Results for Full Year 2017

Signed two strategic partnership agreements for Imeglimin for global rights with potential value of up to approximately $925 million plus royalties on net sales …

Read this Press Release: Poxel Provides Business Update and Reports Results for Full Year 2017
Click here to show the previous slide Click here to show the next slide

Upcoming Events

William Blair Phase 3 Conference

UBS Global Healthcare Conference

Jefferies Global Healthcare Conference

JMP Securities Life Sciences Conference

Kepler Cheuvreux Biotech Days

American Diabetes Association Meeting

Click here to show the previous slide Click here to show the next slide